AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01809847 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Study treatment comprises eight weeks of induction therapy with ofatumumab in combination with high-dose dexamethasone. The first dose of ofatumumab is 300 mg followed by seven infusions of 2000 mg ofatumumab. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Patients who achieved a CR, PR shall proceed to maintenance therapy. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.~An HLA-matched sibling donor or HLA-matched unrelated donor can be identified for approximately 70% of patients. Donor search will be completed within six weeks for 95% of the patients. Patients with a donor will proceed to allogeneic HCT as soon as possible prior to, or during maintenance therapy.
Study NCT01998165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: After intubation, continuous intravenous infusion of remifentanil (0.25 µg/kg/min) is started, while anesthesia is maintained with inhaled or intravenous anesthetics. In cases where sedation by general anesthetics and analgesia by lidocaine does not seem to provide a sufficient means of analgesia at the time of intubation, remifentanil may be used, beginning before intubation. The rate of infusion may be adjusted while monitoring the subject's general condition in 25% to 100% increments or in 25% to 50% decrements every 2 to 5 minutes, but should not exceed 1.3 µg/kg/min.
Study NCT00931606 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: up to 4 subcutaneous doses of placebo given once every 28 days
Study NCT02750488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: 50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
Study NCT02750488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated skin
Description: One site is patched without treatment as control
Study NCT03685227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Nidra
Description: This is a mind/body technique. Specifically, it is a guided meditation, performed while lying down.
Study NCT00780416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424
Description: 750 mg every 8 hours for 12 weeks
Study NCT00576940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reconvan
Description: isocaloric, immunomodulating entral diet
Study NCT00576940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peptisorb
Description: isocaloric, isopeptic standard diet
Study NCT01058707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules
Study NCT02503215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression Stockings
Description: To evaluate the effects of compression stockings on fluid shift and sleep apnea in hemodialysis patients with obstructive sleep apnea
Study NCT00678652 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
Description: 10 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
Study NCT00678652 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
Description: 25 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
Study NCT00678652 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
Description: 50 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
Study NCT00678652 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
Description: 75 μg of Meningococcal 8570 HOPS-G NOMV Vaccine given at 0, 6, and 12 weeks, administered intramuscularly to healthy subjects for duration of study
Study NCT02938819 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal-oriented upper-limb intervention
Description: The Goal-oriented upper-limb intervention evaluated patients' expectations and the environmental factors influencing the performance of the specific task were identified for each of the three tasks. Patients were asked to perform the activity at home. After this, the observable target behavior corresponding to the target activity was determined. Then, an occupational and a physical therapist worked together with the patient to identify the assistance required to perform this activity such as human assistance, technical aids, assistive devices or verbal guidance.
Study NCT03203317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: 2 h insulin clamp
Study NCT03203317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Cycling exercise
Study NCT02001987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered at a dose of 162 mg as SC injection once a week.
Study NCT00780416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 600 - 1000 mg/day based on body weight for 24 weeks
Study NCT00780416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 600 - 1000 mg/day based on body weight for 24 weeks
Study NCT00780416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon Alfa-2b
Description: 1.5 mcg/kg/week for 24 weeks
Study NCT00780416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2b
Description: 1.5 mcg/kg/week for 24 weeks
Study NCT00780416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 600 - 1000 mg/day based on body weight for 48 weeks
Study NCT00780416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 600 - 1000 mg/day based on body weight for 48 weeks
Study NCT00780416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon Alfa-2b
Description: 1.5 mcg/kg/week for 48 weeks
Study NCT00780416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2b
Description: 1.5 mcg/kg/week for 48 weeks
Study NCT03059147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF1126
Description: SF1126 is a dual PI3 kinase/BRD4 inhibitor small molecule. It will be administered IV twice weekly (900 mg/m2 starting dose with escalation to 1000 mg/m2 per dose and 1100 mg/m2 per dose) at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops.
Study NCT02643238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BrainPort
Description: This system is a novel, bionic, non-invasive, vision bypass system that conveys environment images from a spectacle-frame-mounted video-camera to the brain via an electro-tactile tongue array. The electro-tactile stimulation delivered by the tongue-array placed on the tongue allows users to interpret the images of objects in their camera's visual field
Study NCT02643238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BrainPort
Description: This system is a novel, bionic, non-invasive, vision bypass system that conveys environment images from a spectacle-frame-mounted video-camera to the brain via an electro-tactile tongue array. The electro-tactile stimulation delivered by the tongue-array placed on the tongue allows users to interpret the images of objects in their camera's visual field
Study NCT01793766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain modulation
Description: Brain modulation using Eldith/Neuroconn transcranial Direct Current Stimulation device
Study NCT01793766 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham modulation
Study NCT00482625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given PO
Study NCT00482625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergo pancreatectomy
Study NCT03059147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a humanized, IgG4 isotype monoclonal antibody that binds to PD-1 and blocks binding of PD-1 to its ligands PD-L1 and PD-L2. It will be administered at 240 mg IV every 2 weeks until progression or unacceptable toxicity develops.
Study NCT00801905 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac
Description: Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
Study NCT00801905 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lubricant
Description: Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
Study NCT00482625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT00482625 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative studies
Study NCT00482625 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies
Study NCT00482625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT03059056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25mg
Description: Samples from six, healthy, adult, male, smoking, Egyptian volunteers (age: 22-33 years, Average weight: 77.8 kg, Average BMI: 29.2) will be collected at 0, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 h after administration of Empagliflozin 25 mg
Study NCT04061772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib injection
Study NCT04061772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide injection
Study NCT04061772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide injection
Study NCT04061772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmorubicin
Description: Pharmorubicin injection
Study NCT04061772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone tablet
Study NCT01469819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 24 mcg twice a day (BID) for 2 weeks.
Study NCT02721849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga for adolescents
Description: 12 week hatha yoga course for adolescents
Study NCT02721849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga for parents
Description: 12 week hatha yoga course
Study NCT01249378 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: All subjects receive three sequences of a standard breakfast
Description: All subjects receive three sequences of a standard breakfast containing :~* 10 g non emulsified~* or 40 g non emulsified~* or 40 g finely emulsified of milk fat with stable isotope (13C triglyceride). The administration order is determined by randomized allocation. The wash-out period is three weeks. There are not diet or exercise interventions. Only, one week before and three days after, the subjects consume neither naturally enriched in 13C foods or pre/probiotics. In addition, three days before and three days after each test, the subjects receive dietary instructions
Study NCT03917342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EEG measure
Description: Frontal 3-derivation EEG measure under different conditions in pregnancy (healthy vs preeclampsia) and baseline non-pregnant women
Study NCT00992030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: I.V. infusion weekly x 6 weeks at a dose of 375 mg/m2
Study NCT00992030 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Involved field irradiation
Description: Radiation therapy, limited to initially involved nodal sites, will start within four weeks from the last cycle of ABVD chemotherapy and after complete restaging with TAC total-body and PET total-body. The planned total dose is 30,6 Gy.
Study NCT02105688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)
Description: Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
Study NCT02105688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)
Description: Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
Study NCT02001987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
Study NCT02001987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: csDMARDs
Description: csDMARDs (at investigator's discretion) will be administered at a stable dose that was initiated at least 4 weeks prior to Baseline, at investigator's discretion.
Study NCT02818101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis session
Study NCT02105688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet
Description: Placebo Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
Study NCT01762345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pessary (disposable intra-vaginal device)
Description: pessary device(disposable intra-vaginal device)manufactured by Procter \& Gamble
Study NCT03114592 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth tool
Description: The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing the post-hospital discharge stories of two hypothetical AKI survivors. opics of emphasis included NSAID risk awareness and avoidance of volume depletion when ill (Sick Day Protocol).
Study NCT00482625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01066728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CO2 inhalation
Description: Inhalation of CO2 (3% at the source, approximately 1% inhaled) with room air by nasal prongs at 0.5 l/min for 3 days
Study NCT01066728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Study NCT01186991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Description: Onartuzumab will be administered as intravenous (IV) infusion at a dose of 10 milligrams per kilogram (mg/kg) on Day 1 and Day 15 of each 28-day cycle. The dose of onartuzumab will be based on the participant's weight at screening and will remain the same throughout the study.
Study NCT01186991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered as IV infusion at a dose of 10 mg/kg on Day 1 and Day 15 of each 28-day cycle. The dose of bevacizumab will be based on the participant's weight at screening and will remain the same throughout the study.
Study NCT02831088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu2000KWL High-does group
Description: 1st infusion of 750mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
Study NCT02831088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neu2000KWL Low-does group
Description: 1st infusion of 500mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
Study NCT02831088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1st infusion of the same volume of saline in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 hours
Study NCT01186991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered as IV infusion at a dose of 10 mg/kg on Day 1 and Day 15 of each 28-day cycle. The dose of bevacizumab will be based on the participant's weight at screening and will remain the same throughout the study.
Study NCT01186991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered as IV infusion at a dose of 90 milligrams per meter-squared (mg/m\^2) on Day 1, Day 8, and Day 15 of each 28-day cycle.
Study NCT02938819 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard upper limb intervention
Description: The standard upper limb intervention involved active upper limb range of motion, manual dexterity involving grasp and manipulation of small pieces such as marbles and stretching upper limb exercises.
Study NCT01642862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug
Study NCT01642862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug
Study NCT00359866 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT with tomotherapy
Study NCT00887562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Description: 900 mg/day for 1 month
Study NCT00887562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Description: 2250 mg/day for 1 month
Study NCT00887562 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - No idebenone
Study NCT04227730 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: culture and PCR for group B streptococcus
Description: all participants were evaluated by vaginorectal specimens for the detection of GBS, The swabs are placed in Amies transport medium and sent to the microbiology laboratory for testing by conventional PCR assay.
Study NCT00681434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: bilateral upper extremity training
Description: Bilateral symmetrical upper extremity training for proximal control for three hours per week for eight weeks.
Study NCT00681434 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral upper extremity training
Description: Unilateral upper extremity training for proximal extremity for three hours a week for eight weeks.
Study NCT01186991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered as IV infusion at a dose of 90 milligrams per meter-squared (mg/m\^2) on Day 1, Day 8, and Day 15 of each 28-day cycle.
Study NCT01186991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Placebo
Description: Placebo matching to bevacizumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
Study NCT02122874 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Neurostimulation (PENS) of dermatome T7
Description: The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet
Study NCT02122874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Neurostimulation (PENS) of dermatome T7
Description: The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet
Study NCT02122874 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1200 Kcal diet
Study NCT02319317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Risky driving prevention
Description: The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.
Study NCT02319317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group general health promotion
Description: The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
Study NCT01530464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline
Description: Drug will be administered as a single oral dose of 500mg, followed by a 48h washout period.
Study NCT01530464 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ambrisentan
Description: Drug will be administered as a single dose of 5mg, followed by a 48h washout period